Zhongshan Laibo Ruichen Biomedicine Co., Ltd.(Rabpharma), founded in 2021, is a biopharmaceutical company  focused on the research, development, and commercialization of innovative therapeutics for bone and joint diseases.

Our R&D team is led by Prof. Wei Yao, a renowned expert in bone and joint regenerative medicine from UC Davis. The core members consist of scientists and researchers with backgrounds from world-class institutions and extensive experience at leading pharmaceutical companies including Merck, Bayer, and WuXi AppTec, etc. 

Rabpharma specializes in developing first-in-class therapeutics for skeletal disorders. Our first innovative drug,  RAB001, targeting to the treatment of osteonecrosis, has completed Phase I trials both in the U.S. and China. Since December 2024, a Phase II clinical trial has been initiated in 25 hospitals all around China, with full enrollment of all 160 subjects achieved. RAB001d, indicated for knee osteoarthritis (KOA), has enrolled the first patient in its Phase 1b trial in April, 2025. We are also advancing a pipeline of innovative preclinical assets targeting a wider spectrum of bone and joint disorders.

And since establishment, Rabpharma has successfully closed three funding rounds,  accelerating clinical development and pipeline expansion.  

We are committed to our mission: to provide patients with more and better treatment options for bone and joint disorders.